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Abstract: The role of positron emission tomography-computed tom-
ography (PET-CT) in surveillance of patients with nonsmall cell lung
cancer (NSCLC) treated with curatively intended chemoradiotherapy
remains controversial. However, conventional chest X-ray and com-
puted tomography (CT) are of limited value in discriminating post-
radiotherapy changes from tumor relapse. The aim of this study was to
evaluate the clinical value of PET-CT scan in the follow-up for patients
with locally advanced (LA) NSCLC receiving concomitant chemora-
diotherapy (CCRT).
Between 2009 and 2013, eligible patients with stages IIB–IIIB NSCLC
were enrolled in the clinical trial NARLAL and treated in Odense
University Hospital (OUH). All patients had a PET-CT scan scheduled
9 months (PET-CT9) after the start of the radiation treatment in addition to
standard follow-up (group A). Patients who presented with same clinical
stage of NSCLC and received similar treatment, but outside protocol in
OUH during this period were selected as control group (group B). Patients
in group B were followed in a conventional way without PET-CT9. All
patients were treated with induction chemotherapy followed by CCRT.
Group A included 37 and group B 55 patients. The median follow-up
was 16 months. Sixty-six (72%) patients were diagnosed with progression
after treatment. At the time of tumor progression, patients in group A had
better performance status (PS) than those in group B (P¼ 0.02). Because
of death (2 patients), poor PS (3) or retreatment of relapse (9), only 23
patients had PET-CT9 in group A. Eleven (48%) patients were firstly
diagnosed with progression by PET-CT9 without any clinical symptoms
of progression. The median progression-free survival (PFS) was 8.8Schytte, PhD, Henr D,
lfred Hansen, PhD
Additional FDG PET-CT scan at 9 months in surveillance increases
probability of early detection of disease progression in advanced NSCLC
patients treated with curatively intended CCRT.
(Medicine 94(43):e1863)
Abbreviations: CCRT = concurrent chemoradiotherapy, CCT =
concomitant chemotherapy, CT = computed tomography, ESMO =
European Society for Medicine Oncology, FDG = 18-
fluorodeoxyglucose, FEV1 = forced expiratory volume in 1
second, IMRT = intensity modulated radiotherapy, LA = locally
advanced, NCCN = National Comprehensive Cancer Network,
NSCLC = nonsmall cell lung cancer, OS = overall survival, PET-
CT = positron emission tomography-computed tomography, PFS =
progression-free survival, RT = radiotherapy, SBRT = stereotactic
body radiation therapy.
INTRODUCTION
N onsmall cell lung cancer (NSCLC) makes up for around85% of all lung cancer cases which is the leading cause of
cancer death worldwide. Thirty percent of the patients are
inoperable at diagnosis due to the loco-regional advanced
(LA) stage.1 Definitive concurrent chemoradiotherapy (CCRT)
is the standard of care for these patients in good performance
status.1–4 Despite a high objective tumor response rate (60%–
70%) provided by CCRT,2 the prognosis of the patients in
inoperable stages IIIA and IIIB remains poor with 5-year overall
survival (OS) rates at 12% to 16%3,5,6 in clinical trials. The poor
survival is not only caused by a high rate of local and distant
relapses, but also due to comorbidity caused by, for example,
age and smoking. The majority of the relapses are diagnosed
within 2 years after commencement of radiotherapy (RT). The
median progression-free survival (PFS) is 10 to 12 months5–7
and the first and second year PFS rates are 40% and 23%,
respectively.3 In theory, early detection of loco-regional relapse
may increase survival as radical treatment may be possible.
To assess the impact of routine scanning in locally
advanced (LA) NSCLC, Benamore et al8 compared patients
performing intensive radiologic follow-up with those having
less intensive examination. No significant difference in time to
relapse and survival was found. However, the routine tests for
patients in that study were chest X-ray and computed tomogra-
phy (CT) which may be insufficient to discriminate between
postradiotherapy changes and tumor relapse.9 CT scan with or
without contrast every 6 months for 2 years is recommended
for follow-up by the National Comprehensive Cancerdelines.10,11 However, 64% of patients
e present with clinical symptoms outside
visit.8 The local guidelines at our centre
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recommend follow-up with CT scan every 3 months for the first
2 years and every 6 months for another 3 years after definitive
RT. Different guidelines are reflecting the lack of evidence that
early detection and treatment of recurrence leads to a better
outcome.11 18F-Fluorodeoxyglucose (FDG)-positron emission
tomography-computed tomography (PET-CT) scan is a key
imaging examination in the primary diagnosis and staging of
NSCLC due to its superiority in the detection of lung lesion and
mediastinal lymph node, as well as distant metastasis.12 In the
recent years, an increasing amount of studies have shown that
FDG PET-CT was highly accurate for the detection of recur-
rence. FDG PET-CT, as part of a surveillance program, showed
positive findings in 29 (34%) asymptomatic patients with
NSCLC who underwent curative resection.13 Jimenez-Bonilla
et al14 evaluated the value of FDG PET-CT scan in the detection
of relapse in 55 patients which were suspicious of recurrence of
NSCLC and the sensitivity and specificity were 100% and 78%,
respectively. FDG PET combined with diagnostic chest CT
found regional progression in 10 out of 24 patients with early-
stage NSCLC after stereotactic body radiation therapy (SBRT)
while CT scan alone detected no recurrence.15
Nevertheless, the routine use of FDG PET-CT in the
surveillance of patients treated for NSCLC remains controver-
sial. The major issue is that posttreatment inflammation may
persist for quite some time, giving ‘‘false-positive’’ FDG-
uptake.16 Henderson et al17 reported that a substantial pro-
portion of patients with no evidence of recurrence maintained
moderate FDG uptake at 12 months after SBRT. Performing
FDG PET-CT in the initial phase after RT may result in
overestimation of FDG-uptake. According to NCCN and Euro-
pean Society for Medicine Oncology (ESMO) guidelines, PET
is not indicated for routine follow-up.10,11
In our institution, LA-NSCLC patients were offered enroll-
ment in Danish randomized phase II clinical trial (NARLAL)
and had as part of the study a scheduled FDG PET-CT at 9
months (PET-CT9) after commencement of CCRT. Patients
who did not enter the trial, were followed with CT without a
scheduled PET-CT at 9 months, since FDG PET-CT has not
been part of routine follow-up in NSCLC patients treated with
definitive CCRT in our institution.
To evaluate the clinical value of FDG PET-CT scan on
surveillance, we compared patients in the trial with the patients
treated off-trial with conventional follow-up.
MATERIALS AND METHODS
Patients
From May 2009 to August 2013, 37 patients (group A)
with stages IIB–IIIB were treated with definitive CCRT at our
institution as part of the national NARLAL trial. As part of the
trial, they had a PET-CT scheduled at 9 months (1 month,
PET-CT9) after the start of RT in addition to the conventional
follow-up schedule. A group of 55 patients (group B) was
treated outside the trial with curative intent at the department
during this period. These patients were not included in NAR-
LAL because they did not fulfill the eligibility criteria including
low compliance for follow-up due to geographic factor (17
patients), comorbidity (8) (active infection, ischemic heart
disease, and paralysis), side effects of induction chemotherapy
(1), patients’ refusal to participate in the clinical trial (5), other
active malignancies within 5 years (6), benign pleural effusion
Pan et al(3), prior chemotherapy for lung cancer (1), and forced expira-
tory volume in 1 second (FEV1)< 1.0 (1), or other unspecified
reasons (11). The conventional follow-up for group B consisted
2 | www.md-journal.comof CT scan every 3 months after RT start and clinical exam-
inations as previously described.18 FDG PET-CTwas performed
in case recurrent disease was suspected.
To be included in this study, the patients had to have
histologically or cytologically confirmedNSCLC, clinicalAmer-
ican Joint Committee of Cancer stages IIB–IIIB,19 performance
status 0–1 on the ECOG scale, weight loss< 10% in 6 months
and adequate hepatic and renal function. Each patient underwent
basic laboratory studies, CT scans of chest and upper abdomen
with contrast and FDG PET-CT scan before treatment. Baseline
demographics (age, gender, smoking status, performance status,
pathological type, stage) were registered in all patients as well as
the frequency of follow-up visit. Approval was granted by the
Institutional Review Board for conducting this study.
Treatment
All patients in groups A and B were treated with 2 cycles of
induction chemotherapy before CCRT. Chemotherapeutic agents
consisted of i.v. Carboplatin (area under the curve, AUC¼ 5, day
1) and p.o. Vinorelbine (60–80mg/m2, days 1 and 8). Patients in
group A received 60Gy/30 fractions (F) (20 patients) or 66Gy/
33F (17 patients) concurrent with p.o. Vinorelbine 50mg 3 times
aweek duringRTas part of theNARLAL trial.20 Patients in group
B underwent 1 cycle of i.v. Carboplatin (AUC¼ 5) and p.o.
Vinorelbine (60–80mg/m2) as concomitant chemotherapy
(CCT) duringRT 66Gy/33F. All patients were treated 5 fractions
a week by intensity modulated radiation therapy (IMRT) with an
energy of 6MV. All treatment plans were optimized to have 95%
PTV receiving at least 95% prescribed dose. Critical organ dose
tolerances were defined asmaximumdose of esophagus 66Gy,
lung V20 40%, spinal cord 45Gy, heart V50 20%. No
elective nodal irradiation was performed.
Follow-up
Patient surveillance was conducted at the Department of
Oncology and all data were documented in the clinical files.
After RT, follow-up monitoring was at regular intervals: starting
3 months after commencing RT and thereafter every 3 months.
After 2 years the follow-up interval was 6 months for another 3
years. The evaluation at each visit included medical history,
physical examination, pulmonary function, and a CT scan.
When recurrent disease was suspected from a CT scan, an
FDG PET-CT scan was conducted, and, if possible, a tumor
biopsy was taken from the lesion. Patients in group A had a
PETCT9 even if no recurrencewas suspected. Recurrent disease
was defined using RECIST 1.1. No patient was lost for follow-
up. Data cut off was June 1, 2014.
PET-CT Image
FDG PET-CT data were acquired by a General Electric
Discovery FDG PET-CT scanner. Patients had to be fasting for
at least 6 hours before the examination. Patients were injected
with FDGwhich was calculated based on the weight (4–6MBq/
kg). After a rest period of 60minutes (time needed for uptake of
FDG), PET and CT images were acquired. A whole-body PET
scan and a diagnostic low-dose CT was performed from the
vertex of skull to the upper thighs. Tumor is evaluated based on
visual analysis on PET reviewed side-by-side with CT.
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OSwasdefinedfromcommencementofRTtothedateofdeath
orcensoredatthetimeoflastfollow-upifthepatientsaliveattimeof
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evaluation. PFS was defined from the start of RT to the first event
(diseaseprogressionordeathfromanycause).Patientsalivewithout
progressionwerecensoredat thedateof last follow-up.Thedateof
recurrencewas defined as the date of theCTor FDGPET-CT scan
first detecting local–regional or distant recurrence.
Patients and treatment characteristics were summarized by
descriptive statistics. The comparisons of characteristics
between the 2 groups were analyzed by Chi-square test. Survi-
val curvewas estimated using Kaplan–Meier method. A 2-sided
log-rank test was used to evaluate the difference between
survival curves. Avalue of P< 0.05 was considered statistically
significant. Statistical analysis was performed with SPSS (Stat-
istics Package for Social Science) version 19.0 for windows.
RESULTS
A total of 92 patients were enrolled in this study. The
median age of all patients was 66 years (40–81 years). Baseline
characteristics of the entire study population are summarized in
Table 1. There was no significant difference between the 2
groups with respect to age, performance status, sex, smoking
status, histological subtype, T stage, and N stage. The median
potential follow-up of all patients was 23 months, 34 months for
group A and 23 months for group B. No significant difference of
follow-up time was found between the 2 groups (P¼ 0.46).
In group A, 23 (62%) patients underwent FDG PET-CT9
and 14 did not because of death (2 patients), poor PS (3
patients), or retreatment of relapse (9 patients). For these 14
patients, disease progression was identified during the first 8
months of follow-up and their PFS were from 2 to 7.6 months.
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The overall incidence of recurrent disease was 72%. In
group A, 3 (10%) patients had PS 2, 1 (3.3%) had PS 3 and no
TABLE 1. Baseline Characteristics of All Patients (N¼92)
Characteristics Total No. Group A,
Sex
Male 49 22 (6
Female 43 15 (4
Age, y
70 69 29 (7
>70 23 8 (2
Histology
SCC 33 11 (2
Adenocarcinoma 46 23 (6
Others 13 3 (8
PS
0 35 15 (4
1 57 22 (6
T stage
T0–2 52 22 (6
T3–4 40 15 (4
N stage
N0–1 17 4 (1
N2–3 75 33 (8
Smoking
Never 18 5 (1
Smoker

74 32 (8
PS¼ performance status, SCC¼ squamous cell carcinoma.
Never smoker included never smoker and former smokers quitting sm
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.one had PS 4 when diagnosed with recurrent disease. In group
B, 11 (30.6%) patients had PS 2, 2 (5.6%) had PS 3 and 1 (2.8%)
had PS 4. Patients in group A had better PS than those in group
B at the time of relapse (P¼ 0.02). Because of poor PS, 1 patient
in group A and 7 patients in group B could not receive
chemotherapy after disease recurrence.
The treatment after relapse consisted of systemic treatment
(chemotherapy and targeted therapy) or local treatment (surgery
and RT). For local treatment, only 5 patients received surgery
with curative intention including 2 pneumonectomies, 1 adrenal
gland resection, and 1 laparoscopic liver resection in group B,
and 1 bronchoscopic argon plasma coagulation combined with
mediastinal radiation in group A. Some patients underwent
palliative radiation to relieve symptoms. The lines and duration
of systemic treatment, dose and cycles of chemotherapy did not
differ between the 2 groups. The characteristics of patients and
treatment after disease progression are summarized in Table 2.
For the patients with PET-CT9, 16 (70%) patients had
recurrent disease including loco-regional only in 12 (52%), and
both loco-regional and distant in 4 (17%). For 11 (48%)
patients, disease progressions were detected by PET-CT9 with-
out accompanying symptoms. When diagnosed with relapse, 14
(88%) patients with PET-CT9 received chemotherapy and 2
patients rejected chemotherapy for personal reasons.
Overall Survival and Progression-Free Survival
The 1- and 2-year OS rates of the entire population were 82%
(84% in group A and 81% in group B) and 48% (48% vs. 47%),
respectively. Median OS was 23.5 months (21.6 in group A vs.
23.5 in group B). No significant difference of OS existed between
PET-CT in Follow-Up of Patients With NSCLC2 groups (P¼ 0.89) (Fig. 1A). The median PFS was 9.9 months
(8.8 in group A vs. 12.5 in group B). Patients in group B had a
significantly longer overall PFS compare to those in group A
No. (%) Group B, No. (%) P-Value
0) 27 (49) 0.33
0) 28 (51)
8) 40 (73) 0.54
2) 15 (27)
8) 22 (41) 0.13
2) 23 (41)
) 10 (18)
0) 20 (36) 0.69
0) 35 (64)
0) 30 (55) 0.64
0) 25 (45)
1) 13 (24) 0.12
9) 42 (76)
4) 13 (24) 0.23
6) 42 (76)
oking for more than 10 years.
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TABLE 2. Characteristics and Treatment of Patients After Disease Progression
Characteristics Total No. Group A, No. (%) Group B, No. (%) P-Value
PS postprogression
0–1 48 26 (87) 22 (61) 0.02
2 18 4 (13) 14 (39)
Systemic therapy

0 18 5 (17) 13 (36) 0.11
1 line 29 17 (56) 12 (33)
2 lines 19 8 (27) 11 (31)
Duration of systemic therapy
3 mo 38 15 (50) 23 (64) 0.40
3–6 mo 15 9 (30) 6 (17)
>6 mo 13 6 (20) 7 (19)
Re-chemo
No 20 6 (20) 14 (39) 0.10
Yes 46 24 (80) 22 (61)
Chemo-cycles
0 20 6 (20) 14 (39) 0.23
1–6 cycles 32 16 (53) 16 (44)
7 cycles 14 8 (27) 6 (17)
Chemo-dose
100% 39 21 (87) 18 (82) 0.90
75% 7 3 (13) 4 (18)
Pan et al Medicine  Volume 94, Number 43, October 2015(P¼ 0.04) (Figure 1B). Cumulative incidences of death were
similar between 2 groups (Figure 1C). However, hazard function
PFS showed that patients in group A had higher risk of relapse
than in group B (Figure 1D). The slopes of the cumulative hazard
were almost the same before and after 9 months which showed
that the difference between the curves was within the 9-month

Systemic therapy included chemotherapy and targeted therapy.time window. For patients with progression, median OS was 33.2
months in group A and 22.2 months in group B, but there was no
significant difference (P¼ 0.81).
DISCUSSION
FDG PET-CTscanhas been widely usedasa routine imaging
modality in thediagnosisofNSCLC.However, itsvalue insurveil-
lance is still controversial. Recent studies have shown that FDG
PET-CTisvaluableindetectinglocal recurrenceduringfollow-up,
since it is superior in distinguishing recurrence from benign con-
ditions such as atelectasis, scar, and radiation fibrosis compared to
conventional imaging.21–23 In this study, wescheduled FDG PET-
CTscanforlocaladvancedNSCLCpatientswithCCRTtoassessthe
roleofFDGPET-CTinsurveillance.TheeffectofFDGPET-CTin
detecting local recurrence was retrospectively assessed in 154
patients with inoperable NSCLC receiving SBRT by Takeda
et al.22 All of 17 local recurrent tumors were diagnosed by FDG
PET-CT while CT had a limited ability to distinguish tumor
recurrence from scar or fibrotic change.22 When annually FDG
PET-CT was added to postoperative surveillance in NSCLC after
curativeresection,26(52%)recurrencesweredetectedbybothFDG
PET-CT and chest CT and 19 (37%) recurrences were confirmed
only by FDG PET-CT.24
Follow-up FDG PET-CT is useful for post treatment
evaluation in patients with NSCLC, but its clinical value
depends mainly on when it is performed. Van Loon et al23
followed 100 NSCLC patients 3 months after curatively
intended RT chemotherapy with FDG PET-CT. FDG
4 | www.md-journal.comPET-CT detected recurrent disease potentially amenable for
radical treatment in 3% of patients. Thus, it seemed that only a
very small proportion benefited from surveillance using FDG
PET-CT scan. The reason may be low accuracy of FDG PET-
CT in the initial phase after RT due to radiation changes such as
inflammation, congestion, or edema.25 Furthermore, only a few
patients relapsed in the first 3 months after treatment. According
to 10- to 12-month median PFS5–7 in patients with inoperably
advanced NSCLC, patients in our study performed FDG PET-
CT at 9 months after the start of RT. In 37 patients in group A,
23 (62%) underwent PET-CT9 and 11 (48%) were firstly
diagnosed progression by this FDG PET-CT while no patient
had clinical symptoms. It suggested that progressive disease not
inducing any abnormality was detected early by the planned
FDG PET-CT scan. In the study by Toba et al, an FDG PET-CT
was performed in NSCLC patients without clinical and radio-
logical recurrence after curative resection at least once a year. In
18 asymptomatic patients with recurrent disease, 17 (94%) were
correctly diagnosed by FDG PET-CT.26
With conventional follow-up without use of FDG PET-CT,
suspicion of NSCLC relapse frequently occurs when patients
were symptomatic, but there may be limited therapeutic option at
diagnosis and little treatment benefit because of poor PS or large
tumor burden. Cisplatin-based chemotherapy improves survival
and quality of life in patients with PS 0–1, while the patients in
poor PS have less benefit of chemotherapy.27,28 This may indicate
that early detection of a relapse by use of FDG PET-CT in
asymptomatic patients may increase survival. In our study,
patients in group A with planned PET-CT9 had a better perform-
ance status than those in group B with only conventional follow-
up schedule after diagnosis of progression (P¼ 0.02). More
patients in group B did not receive chemotherapy compared with
those in group A (39% vs. 20%) although there was no significant
difference. This may suggest that early detection of progression
lead to better PS and a higher chance of chemotherapy. For
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
A B
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FIGURE 1. Overall survival, progression-free survival and cumulative hazard OS and PFS in 2 groups. OS (A) was not significantly different
in
rou
ths
Medicine  Volume 94, Number 43, October 2015 PET-CT in Follow-Up of Patients With NSCLCpatients with NSCLC who had relapsed after complete resection,
PS at the diagnosis of recurrence was the independent prognostic
factor of postrecurrence survival.28 Patients with better PS at
recurrence had a higher rate of application of chemotherapy and
selection of best supportive care.28
Until now, researches have failed to demonstrate that early
detection of recurrent disease by FDG PET-CT improved
survival in NSCLC, but there might be indications that patients
with loco-regional relapse survived longer than those with
in 2 groups, while PFS (B) was significantly longer in group B than
groups (C). However, hazard function PFS showed that patients in g
cumulative hazard PFS were almost the same before and after 9mon
the 9-month time window.distant metastases when diagnosed relapse by FDG PET-
CT.14 In our study, the median PFS was 3.8 months shorter
in group A (8.8 months) than in group B (12.5 months) and the
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.risk of recurrence was higher in group A reflecting that disease
progression was detected earlier in patients performing
additional FDG PET-CT at 9 months than those with only
conventional follow-up. However, no statistically significant
OS benefit was observed between the 2 groups. There may be a
bias between groups A and B in our study, but it is expected to
be such that group A is doing better than group B since some of
the patients in group B had comorbidities that prevented them
for being in the NARLAL trial.
group A. Cumulative incidences of death were similar between 2
p A had higher risk of relapse than in group B (D). The slopes of the
which showed that the difference between the curves were withinPFSisacommonlyusedendpointinclinicaltrialstoassessthe
effect of cancer treatment but it is important to be aware that
measured values depend on the method used to measure PFS.
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ComparingPFSdirectly indifferent studiesmaylead toa leadtime
bias when the follow-up schedules are not identical. The intensive
follow-upingroupAisthereasonfortheworsePFSobservedherein
comparison with group B since the OS is remarkable similar.
In summary, our study demonstrates that additional FDG
PET-CT scan at 9 months in surveillance increases probability
of early detection of disease progression in advanced NSCLC
patients treated with curatively intended CCRT. However, this
study has several limitations. First, it was not a prospective
study. The control group consisted of patients receiving similar
but not identical therapeutic regimen. Secondly, the sample size
was small and the statistical power of testing difference in
Pan et altreatment and survival between 2 groups was limited. Further
studies are needed to analyze the value of FDG PET-CT on
follow-up of patients with NSCLC after curatively intended RT.
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